Atefeh Naeimifar, Saman Ahmad Nasrollahi, Aniseh Samadi, Zeinab Aryanian, Hamid Akbari Javar, Mohammadreza Rouini, Mansour Nassiri Kashani, Alireza Firooz
{"title":"评价含有纳米脂质体磷酸鲁索利替尼的局部乳凝胶治疗轻度特应性皮炎的耐受性和疗效:一项前后单组试点研究。","authors":"Atefeh Naeimifar, Saman Ahmad Nasrollahi, Aniseh Samadi, Zeinab Aryanian, Hamid Akbari Javar, Mohammadreza Rouini, Mansour Nassiri Kashani, Alireza Firooz","doi":"10.1080/09546634.2022.2112138","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib phosphate (RuxoLip) emulgel in mild AD.</p><p><strong>Methods: </strong>Clinical evaluation was conducted on 10 patients with mild AD. The efficacy of the product as well as patient satisfaction was evaluated by local scoring atopic dermatitis (SCORAD) of AD. In addition, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, sebum, erythema, melanin content, and ultrasonographic parameters were measured before, and two and four weeks after treatment.</p><p><strong>Results: </strong>Four weeks of treatment reduced SCORAD, itching, and burning (<i>p</i> = .001, .001, and .001, respectively) and increased hydration, sebum, and epidermal density (<i>p</i> = .001, .018, and .037, respectively). SCORAD and other skin biophysical parameters improved within two weeks of treatment and then were in plateau for up to four weeks.</p><p><strong>Conclusions: </strong>The topical ruxolitinib emulgel has good short-term efficacy and tolerability.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3160-3164"},"PeriodicalIF":2.9000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study.\",\"authors\":\"Atefeh Naeimifar, Saman Ahmad Nasrollahi, Aniseh Samadi, Zeinab Aryanian, Hamid Akbari Javar, Mohammadreza Rouini, Mansour Nassiri Kashani, Alireza Firooz\",\"doi\":\"10.1080/09546634.2022.2112138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib phosphate (RuxoLip) emulgel in mild AD.</p><p><strong>Methods: </strong>Clinical evaluation was conducted on 10 patients with mild AD. The efficacy of the product as well as patient satisfaction was evaluated by local scoring atopic dermatitis (SCORAD) of AD. In addition, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, sebum, erythema, melanin content, and ultrasonographic parameters were measured before, and two and four weeks after treatment.</p><p><strong>Results: </strong>Four weeks of treatment reduced SCORAD, itching, and burning (<i>p</i> = .001, .001, and .001, respectively) and increased hydration, sebum, and epidermal density (<i>p</i> = .001, .018, and .037, respectively). SCORAD and other skin biophysical parameters improved within two weeks of treatment and then were in plateau for up to four weeks.</p><p><strong>Conclusions: </strong>The topical ruxolitinib emulgel has good short-term efficacy and tolerability.</p>\",\"PeriodicalId\":15639,\"journal\":{\"name\":\"Journal of Dermatological Treatment\",\"volume\":\"33 8\",\"pages\":\"3160-3164\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatological Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09546634.2022.2112138\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2112138","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study.
Background: Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib phosphate (RuxoLip) emulgel in mild AD.
Methods: Clinical evaluation was conducted on 10 patients with mild AD. The efficacy of the product as well as patient satisfaction was evaluated by local scoring atopic dermatitis (SCORAD) of AD. In addition, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, sebum, erythema, melanin content, and ultrasonographic parameters were measured before, and two and four weeks after treatment.
Results: Four weeks of treatment reduced SCORAD, itching, and burning (p = .001, .001, and .001, respectively) and increased hydration, sebum, and epidermal density (p = .001, .018, and .037, respectively). SCORAD and other skin biophysical parameters improved within two weeks of treatment and then were in plateau for up to four weeks.
Conclusions: The topical ruxolitinib emulgel has good short-term efficacy and tolerability.
期刊介绍：
The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
